Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
1 Assignment
0 Petitions
Accused Products
Abstract
A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer. The protein or polypeptide is selected from the group consisting of (a) proteins or polypeptides capable of externally binding said colloidal particles; (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and (c) proteins or polypeptides that include a consensus sequence of S/T-X/I/V-I/V/Q/S-S/T-X-X-X-E, where X may be any amino acid, and S,T,L,I,V,E and Q have their standard meanings. The protein or polypeptide is not Factor VIII (FVIII) and is not encapsulated in the colloidal particles.
17 Citations
52 Claims
-
1-27. -27. (canceled)
-
28. A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles, said particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,
wherein said protein or polypeptide is selected from the group consisting of: -
(a) proteins or polypeptides capable of externally binding said colloidal particles;
(b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
(c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;
wherein said protein or polypeptide is not Factor VIII (FVIII), and wherein said protein or polypeptide is not encapsulated in said colloidal particles. - View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)
-
-
47. Method of treatment of a patient suffering from a disease comprising administrating to said patient a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide effective in the treatment of the disease and colloidal particles, said colloidal particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,
wherein said protein or polypeptide is selected from the group consisting of: -
(a) proteins or polypeptides capable of externally binding said colloidal particles;
(b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
(c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;
wherein said protein or polypeptide is not Factor VIII (FVIII), and wherein said protein or polypeptide is not encapsulated in said colloidal particles. - View Dependent Claims (48, 49)
-
-
50. Method of treatment of a patient suffering from a disease comprising administrating to said patient a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide effective in the treatment of the disease and colloidal particles, said colloidal particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,
wherein said protein or polypeptide is selected from the group consisting of: -
(a) proteins or polypeptides capable of externally binding said colloidal particles;
(b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
(c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;
wherein said colloidal particles and said protein or polypeptide are administered separately, and wherein said protein or polypeptide is not encapsulated in said colloidal particles. - View Dependent Claims (51, 52)
-
Specification